Abstract. We previously showed that the -1131T→C polymorphism (rs662799) of the apolipoprotein A-V gene (APOA5) and the C→T polymorphism (rs6929846) of the butyrophilin, subfamily 2, member A1 gene (BTN2A1) were significantly associated with an increased serum concentration of triglycerides, a decreased serum concentration of high density lipoprotein (HDL)-cholesterol, and the prevalence of metabolic syndrome (MetS) in Japanese individuals. The purpose of the present study was to examine whether these polymorphisms synergistically affect the prevalence of dyslipidemia and MetS in East Asian populations. The study populations comprised 7471 Japanese and 3529 Korean individuals in the dyslipidemia study, and 3474 Japanese and 1671 Korean individuals in the MetS study. Multivariable logistic regression analysis of combined genotypes with adjustment for age, gender and diabetes mellitus revealed that rs662799 and rs6929846 significantly and synergistically affected dyslipidemia. Japanese or Korean individuals with the C allele of APOA5 and the T allele of BTN2A1 had a 2.05-or 1.92-fold increased risk for hypertriglyceridemia and a 1.82-or 1.56-fold increased risk for hypo-HDL-cholesterolemia, respectively, compared to those with the TT genotype of APOA5 and the CC genotype of BTN2A1. Similar analysis with adjustment for age and gender revealed that Japanese individuals, but not Korean individuals, with the C allele of APOA5 and the T allele of BTN2A1 had a 2.87-fold increased risk for MetS compared to those with the TT genotype of APOA5 and the CC genotype of BTN2A1. Genetic variants of APOA5 and BTN2A1 may synergistically affect the prevalence of dyslipidemia in East Asian populations and of MetS in Japanese individuals.
Introduction
The prevalence of dyslipidemia and metabolic syndrome (MetS), which are important risk factors for cardiovascular diseases (1, 2) , is increasing among Asian populations (3, 4) . The etiologies of dyslipidemia and MetS are highly complex, with both genetic and environmental factors being thought to play crucial roles. Although recent genome-wide association studies have implicated several loci and candidate genes in predisposition to dyslipidemia (5-7) and MetS (8, 9) in Caucasian populations, the genes that confer susceptibility to these conditions in Asian populations remain to be identified definitively.
We previously showed that the -1131T→C polymorphism (rs662799) of the apolipoprotein A-V gene (APOA5) and the C→T polymorphism (rs6929846) of the butyrophilin, subfamily 2, member A1 gene (BTN2A1) were significantly associated with the prevalence of dyslipidemia (10, 11) and MetS (12) (13) (14) in Japanese individuals. Given that gene-gene interactions may play important roles in the development of multifactorial complex disorders, we hypothesized that rs662799 of APOA5 and rs6929846 of BTN2A1 may synergistically affect the development of dyslipidemia and MetS. We have thus examined the association of rs662799 of APOA5, rs6929846 of BTN2A1, or combined genotypes for these polymorphisms with the prevalence of dyslipidemia or MetS in Japanese and Korean individuals.
Materials and methods
Study population. The study populations comprised 7471 Japanese and 3529 Korean individuals in the dyslipidemia study, and 3474 Japanese (2744 subjects with MetS, 730 controls) and 1671 Korean (1294 subjects with MetS, 377 controls) individuals in the MetS study. Japanese subjects either visited outpatient clinics of or were admitted to the participating hospitals (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General Medical Center, Gifu; Japanese Red Cross Nagoya First Hospital, Nagoya; Inabe General Hospital, Inabe, and Hirosaki University Hospital and Hirosaki Stroke Center, Hirosaki, Japan) between October 2002 and March 2009 because of various symptoms or for an annual health checkup, or who were recruited to populationbased cohort studies of aging and age-related diseases in Nakanojo and Tokyo, Japan. The study protocol complied with the Declaration of Helsinki and was approved by the Ethics Committees of Human Research of Mie University Graduate School of Medicine, Hirosaki University Graduate School of Medicine, Tokyo Metropolitan Institute of Gerontology, and participating hospitals. Written informed consent was obtained from each subject.
Korean subjects were drawn from the institutional patient databases of the Cardiovascular Genome Center and Infarction Prognosis Study Registry, Severance Cardiovascular Hospital, Seoul. The study protocol complied with the guidelines for Genome/Genetic Research issued by the Korean government and was approved by the Institutional Review Board of Yonsei University. Written informed consent was obtained from each participant.
Diagnosis of MetS was based on a modified version of the definition proposed by the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity (3) . In this modified version, which was also used in the West of Scotland Coronary Prevention Study (15) and the Women's Health Study (16) , body mass index (BMI) replaces waist circumference, given that cut-off values of waist circumferences for men and women are still controversial in Japan. On the basis of the recent recognition of a need to revise BMI criteria for obesity in Japanese and other Asian populations (17), we set the cut-off point for obesity as a BMI of ≥25 kg/m 2 . A total of 4038 subjects with MetS had thus three or more of the following five components: i) a BMI of ≥25 kg/m 2 ; ii) a serum concentration of triglycerides of ≥1.65 mmol/l (150 mg/dl) or drug treatment for elevated triglycerides; iii) a serum concentration of high density lipoprotein (HDL)-cholesterol of <1.04 mmol/l (40 mg/dl) for men or <1.30 mmol/l (50 mg/dl) for women, or drug treatment for reduced HDL-cholesterol; iv) a systolic blood pressure of ≥130 mmHg or diastolic blood pressure of ≥85 mmHg, or drug treatment for hypertension; and v) a fasting plasma glucose level of ≥5.50 mmol/l (100 mg/dl) or drug treatment for elevated glucose. History of obesity, dyslipidemia, hypertension, or diabetes mellitus was evaluated from a detailed questionnaire. Control groups consisted of 1107 individuals who had none of the five components of diagnostic criteria for MetS. Individuals with coronary heart disease, ischemic or hemorrhagic stroke, or other vascular diseases were excluded from the control groups. Individuals with type 1 diabetes mellitus, maturity-onset diabetes of the young, diabetes mellitus associated with mitochondrial diseases or single gene disorders, pancreatic diseases including severe pancreatitis and pancreatic tumor, or other endocrinologic diseases were excluded from the study. Individuals with severe hepatic or renal diseases, chronic inflammatory diseases, or cancers were also excluded.
Measurement of blood pressure, serum lipid profile, and plasma glucose. Blood pressure was measured at least twice with subjects having rested in the sitting position for >5 min; the measurements were taken by a skilled physician according to the guidelines of the American Heart Association (18) . Venous blood was collected in the early morning after the subjects had fasted overnight and before they had begun lipid-lowering treat ment as appropriate. Blood samples were centrifuged at 1600 x g for 15 min at 4˚C, and serum was separated and stored at -30˚C until analysis. Serum concentrations of triglycerides, HDL-cholesterol, and low density lipoprotein (LDL)-cholesterol (10) and plasma glucose levels (19) were measured as previously described.
Genotyping of polymorphisms. For Japanese individuals, venous blood (7 ml) was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), peripheral blood leukocytes were isolated, and genomic DNA was extracted from these cells with a DNA extraction kit (Genomix; Talent, Trieste, Italy). Genotypes of rs662799 of APOA5 and rs6929846 of BTN2A1 were determined at G&G Science (Fukushima, Japan) by the multiplex beadbased Luminex assay, a method that combines polymerase chain reaction (PCR) and sequence-specific oligonucleotide probes with suspension array technology (Luminex, Austin, TX). Genotyping involved PCR amplification, hybridization, streptavidin-phycoerythrin reaction, and measurement of fluorescence. Detailed genotyping methodology was previously described (12, 20, 21) .
For Korean individuals, genomic DNA was extracted from 5 ml of whole blood with the use of a DNA isolation kit (Wizard Genomic DNA purification kit; Promega, Madison, WI). Genotypes of rs662799 of APOA5 and rs6929846 of BTN2A1 were determined with the use of a TaqMan fluorogenic 5' nuclease assay (Applied Biosystems, Foster City, CA). Genotyping methodology was previously described (20, 22) .
Statistical analysis. Quantitative data were compared between two groups by the unpaired Student's t-test. Categorical data were compared by the χ 2 test. Allele frequency was estimated by the gene counting method, and the χ 2 test was used to identify departures from the Hardy-Weinberg equilibrium. Allele frequencies of rs662799 in APOA5 and rs6929846 in BTN2A1 were compared between subjects with MetS and controls by the χ 2 test. Multivariable logistic regression analysis was performed with hypertriglyceridemia (1, serum triglyceride concentration of ≥1.65 mmol/l; 0, that of <1.65 mmol/l), hypo-HDL-cholesterolemia (1, serum HDL-cholesterol concentration of <1.04 mmol/l; 0, that of ≥1.04 mmol/l), or hyper-LDLcholesterolemia (1, serum LDL-cholesterol concentration of ≥3.64 mmol/l; 0, that of <3.64 mmol/l) as a dependent variable and independent variables including age, gender (0, woman; 1, man), the prevalence of diabetes mellitus (0, no history of diabetes mellitus; 1, positive history), and genotypes for APOA5 and/or BTN2A1 in the dyslipidemia study; or with MetS as a dependent variable and independent variables including age, gender, and genotypes for APOA5 and/or BTN2A1; and P-values, odds ratios, and 95% confidence intervals were calculated. Genotypes for APOA5 or BTN2A1 were assessed according to dominant (0, wild-type homozygote; 1, heterozygote and variant homozygote) and recessive (0, wild-type homozygote and heterozygote; 1, variant homozygote) genetic models. To compensate for multiple comparisons of genotypes with dyslipidemia or MetS, we applied Bonferroni's correction for statistical significance of association. The significance level was thus P<0.002 (0.05/27 tests) in Tables II and III ; or P<0.006 (0.05/9 tests) in Tables V and VI. In other statistical analyses, a P-value of <0.05 was considered significant. Statistical significance was examined by two-sided tests performed with JMP version 6.0 and JMP Genomics version 3.2 software (SAS Institute, Cary, NC).
Results

Association of polymorphisms of APOA5 and BTN2A1 with serum concentrations of triglycerides, HDL-cholesterol, and LDL-cholesterol.
The characteristics of Japanese and Korean subjects are shown in Table I . The rs662799 of APOA5 was significantly [P<0.004 (0.05/12 tests)] associated with serum concentrations of triglycerides and HDL-cholesterol, but not LDL-cholesterol, in Japanese and Korean individuals (data not shown). In both populations, the serum concentrations of triglycerides were greater, whereas the serum concentrations of HDL-cholesterol were lower, in individuals with the C allele than in those with the TT genotype or in individuals with the CC genotype than in those with the T allele. The rs6929846 of BTN2A1 was significantly associated with serum concentrations of triglycerides and HDL-cholesterol, but not LDL-cholesterol, in Japanese individuals (data not shown). The serum concentrations of triglycerides were greater, whereas the serum concentrations of HDL-cholesterol were lower, in individuals with the T allele than in those with the CC genotype. There was no association between rs6929846 of BTN2A1 and serum concentrations of triglycerides, HDL-cholesterol, or LDL-cholesterol in Korean individuals. The genotype distributions for rs662799 and rs6929846 in Japanese and Korean individuals were all in HardyWeinberg equilibrium (data not shown).
We examined the relations of combined genotypes for rs662799 of APOA5 and rs6929846 of BTN2A1 to serum concentrations of triglycerides, HDL-cholesterol, and LDL-cholesterol in Japanese and Korean individuals (Table II) . The serum concentrations of triglycerides among Japanese and Korean individuals were increased by 41 and 24%, respectively, whereas the serum concentrations of HDL-cholesterols were decreased by 35 and 4%, respectively, in individuals with the C allele of APOA5 and the T allele of BTN2A1 compared to those with the TT genotype of APOA5 and the CC genotype of BTN2A1. Multivariable logistic regression with adjustment for age, gender, and the prevalence of diabetes mellitus revealed that rs662799 of APOA5 was significantly [P<0.004 (0.05/12 tests)] related to hypertriglyceridemia in Japanese and Korean individuals (dominant and recessive models) and to hypo-HDL-cholesterolemia in Japanese (dominant and recessive models) and Korean (dominant model) individuals, with the C allele representing a risk factor for these conditions (data not shown). Similar analyses revealed no relation of rs6929846 of BTN2A1 to dyslipidemia in Japanese or Korean individuals (data not shown). Multivariable logistic regression analysis of combined genotypes for rs662799 of APOA5 and rs6929846 of BTN2A1 with adjustment for age, gender, and the prevalence of diabetes mellitus revealed that Japanese or Korean individuals with the C allele of APOA5 and the T allele of BTN2A1 had a 2.05-or 1.92-fold increased risk for hypertriglyceridemia, respectively and a 1.82-or 1.56-fold increased risk for hypo-HDL-cholesterolemia, respectively, compared to those with the TT genotype of APOA5 and the CC genotype of BTN2A1 (Table III) .
Association of polymorphisms of APOA5 and BTN2A1 with
MetS. The characteristics of Japanese and Korean subjects with MetS and controls are shown in Table IV . For Japanese individuals, age, the frequency of men, BMI, the prevalence of smoking as well as systolic and diastolic blood pressure, serum concentrations of triglycerides and creatinine, and fasting plasma glucose levels were greater, whereas the serum concentration of HDL-cholesterol was lower, in subjects with MetS than in controls. For the Korean individuals, the frequency of men, BMI, the prevalence of smoking as well as systolic and diastolic blood pressure, serum concentrations of triglycerides and creatinine, and fasting plasma glucose levels were greater, whereas age and the serum concentration of HDL-cholesterol were lower, in subjects with MetS than in controls.
Comparison of allele frequencies between subjects with MetS and controls by the χ 2 test revealed that rs662799 of APOA5 was significantly [P<0.025 (0.05/2 tests)] associated with MetS in Japanese and Korean individuals (data not shown). Similar analysis revealed that rs6929846 of BTN2A1 was significantly associated with MetS in Japanese individuals, but not in Korean subjects (data not shown). Genotype distributions of rs662799 and rs6929846 were in Hardy-Weinberg equilibrium among subjects with MetS and controls in Japanese and Korean individuals (data not shown). Combined genotype analysis revealed that the prevalence of MetS was significantly [P<0.006 (0.05/9 tests)] increased in Japanese individuals with the C allele of APOA5 and any genotype of BTN2A1 compared to those with the TT genotype of APOA5 and the CC genotype of BTN2A1 (Table V) . No relation was detected between combined genotypes and MetS in Korean individuals.
Multivariable logistic regression analysis with adjustment for age and gender revealed that rs662799 of APOA5 was significantly [P<0.01 (0.05/4 tests)] associated with MetS in Japanese individuals (dominant and recessive models), but not in Korean subjects, with the C allele representing a risk factor for this condition (data not shown). Similar analysis revealed that rs6929846 of BTN2A1 was significantly associated with MetS in Japanese individuals (dominant model), but not in Korean subjects, with the T allele representing a risk factor for this condition (data not shown). Multivariable logistic regression analysis of combined genotypes with adjustment for age and gender revealed that individuals with the C allele of APOA5 and the T allele of BTN2A1 had a 2.87-fold increased risk for MetS compared to those with the TT genotype of APOA5 and the Table II . Serum concentrations of triglycerides, HDL-cholesterol, and LDL-cholesterol according to combined genotypes for rs662799 of APOA5 and rs6929846 of BTN2A1 in Japanese and Korean individuals. CC genotype of BTN2A1 in Japanese individuals (Table VI) . There was no relation between combined genotypes and MetS in Korean individuals.
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TC + CC -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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Discussion
Although genetic epidemiological studies have shown that genetic variants contribute to individual susceptibility to dyslipidemia and MetS in Caucasian populations (5-9), the genetic basis of these conditions in Asian populations remains to be fully identified. We have now shown that rs662799 of APOA5 and rs6929846 of BTN2A1 synergistically influenced the prevalence of hypertriglyceridemia and hypo-HDLcholesterolemia in Japanese and Korean individuals and of MetS in Japanese individuals. Apolipoprotein A-V plays a pivotal role in the regulation of serum concentrations of triglycerides (23, 24) . Apolipoprotein A-V was shown to exhibit a high affinity, low elasticity, and slow binding kinetics at hydrophobic interfaces (25) , properties that may retard the assembly of triglyceride particles. Apolipoprotein A-V may thus reduce very low density lipoprotein (VLDL)-triglyceride levels by both downregulating hepatic VLDL synthesis and increasing VLDL clearance. Given its location in the promoter region, the -1131T→C polymorphism (rs662799) of APOA5 may affect the regulation of gene transcription and thereby influence the serum level of apolipoprotein A-V. Peroxisome proliferator-activated receptor-α (PPARα) was shown to regulate the expression of APOA5 via the PPAR response element at position -271 to -259 in the promoter lesion of APOA5 (26, 27) . PPARα agonists induced the expression of APOA5 in primary liver cells, and caused a dramatic increase in the β-oxidation of the liver and the fatty acid-dependent energy generation. The rs662799 of APOA5 may affect the affinity of PPARα for the PPAR response Table IV . Characteristics of study subjects in the metabolic syndrome (MetS) study. element (27, 28) , thereby influence the diversion of triglycerides from the secretory into the oxidative pathway. We previously showed that rs662799 of APOA5 was significantly associated with the prevalence of hypertriglyceridemia, hypo-HDLcholesterolemia (10), and MetS (12) in Japanese individuals.
We have now shown that this polymorphism is associated with increased serum concentrations of triglycerides, decreased serum concentrations of HDL-cholesterol, and an increased risk for hypertriglyceridemia and hypo-HDL-cholesterolemia in Korean individuals. The butyrophilin, subfamily 2, member A1 (BTN2A1) belongs to BTN superfamily, and is a cell surface transmembrane glycoprotein that has roles in lipid, fatty acid, and sterol metabolism (Entrez Gene, NCBI). We previously showed that the T allele of rs6929846 of BTN2A1 was associated with an increased risk for myocardial infarction, an increase in the serum concentration of high sensitivity C-reactive protein as well as with increased transcription activity of BTN2A1 (20) . Overexpression of BTN2A1 decreased the expression of elastin mRNA and increased the mRNA expression of matrix metallopeptidase 3 and interleukin 5 (20) . We also showed that rs6929846 of BTN2A1 was significantly associated with increased serum concentrations of triglycerides and decreased serum concentrations of HDL-cholesterol (11), and with a increased risk for MetS (14) in Japanese individuals. These observations suggest that the T allele of rs6929846 of BTN2A1 may accelerate inflammatory, atherosclerotic, and thrombotic processes (20) . In the present study, however, rs6929846 alone was not related to serum concentrations of triglycerides, HDL-cholesterol, or LDL-cholesterol, or the prevalence of MetS in Korean individuals.
Previous studies suggested that the effect of rs662799 of APOA5 on the regulation of serum triglycerides was modulated by other genetic and environmental factors (29) (30) (31) (32) . Genetic variants of APOA5 (rs662799) and APOE (rs429358, rs7412) synergistically affected serum concentrations of triglycerides (29) . In simultaneous analysis of four polymorphisms of LPL (rs320, rs328, rs1801177, rs268), two polymorphisms of APOA5 (rs662799, rs3135506), and two polymorphisms of APOE (rs429358, rs7412), serum concentrations of triglycerides were significantly increased in individuals with two or three triglycerides-raising alleles among these polymorphisms (30) . In addition, environmental factors, including a high-fat and high-calorie diet and physical inactivity, may affect gene-gene interactions as well as the development of dyslipidemia (31, 32) .
We have now shown that polymorphisms of APOA5 and BTN2A1 synergistically affected the development of dyslipidemia in East Asian populations and of MetS in Japanese individuals. Systemic inflammation has been shown to play an important role in an increase in insulin resistance, the development of dyslipidemia, and the progression of MetS (33) . Acceleration of inflammatory processes by the T allele of rs6929846 in BTN2A1 might influence the effects of rs662799 of APOA5 on lipid metabolism, resulting in the synergistic effects of rs662799 and rs6929846 on the development of hypertriglyceridemia, hypo-HDL-cholesterolemia, or MetS.
There are some limitations to our study: i) given that the study subjects comprised of only Japanese and Korean populations, validation of our findings in other ethnic groups is required. ii) the functional relevance of the synergistic effects of APOA5 and BTN2A1 on dyslipidemia or MetS has Table VI . Multivariable logistic regression analysis of the metabolic syndrome and combined genotypes for rs662799 of APOA5 and rs6929846 of BTN2A1 in Japanese and Korean individuals. ------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------ not been determined; iii) the criteria for diagnosis of MetS proposed by the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity were modified (waist circumference was replaced with BMI), as was also the case in the West of Scotland Coronary Prevention Study (15) and Women's Health Study (16) .
APOA5
genotype TT TC + CC ------------------------------------------------------------------------------------------------------------
In conclusion, our present results suggest that polymorphisms of APOA5 and BTN2A1 may synergistically affect the development of dyslipidemia in East Asian populations and of MetS in Japanese individuals. Determination of combined genotypes for rs662799 of APOA5 and rs6929846 of BTN2A1 may prove informative for assessment of the genetic risk for dyslipidemia or MetS in the East Asian populations.
